Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOPURIN vs AMOSENE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.
Gout prophylaxis,Management of hyperuricemia in patients with cancer undergoing chemotherapy,Prevention of recurrent calcium oxalate calculi in patients with hyperuricuria
Anxiety disorders,Short-term relief of anxiety symptoms,Preoperative sedation,Alcohol withdrawal syndrome
200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.
400 mg orally twice daily for 14 days
Allopurinol: 1-2 hours; oxypurinol: 18-30 hours (renal function dependent). Accumulation in renal failure; half-life of oxypurinol may exceed 100 hours in ESRD.
Terminal elimination half-life is 18-22 hours in adults with normal renal function; prolonged to 30-50 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via aldehyde oxidase to oxypurinol (alloxanthine), which is also active; minor metabolism by xanthine oxidase.
Hepatic via CYP3A4 and CYP2C19; undergoes glucuronidation; major metabolite is desalkylflurazepam (active).
Renal (primarily as unchanged drug and active metabolite oxypurinol): ~70% urinary excretion; remainder biliary/fecal. Dose adjustment required in renal impairment.
Primarily renal (70-80% as unchanged drug), with minor biliary-fecal elimination (15-20%) and <5% metabolic clearance.
Allopurinol: <1%; oxypurinol: ~20% (primarily to albumin). Negligible displacement interactions.
95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Allopurinol: ~1.6 L/kg; oxypurinol: ~0.6 L/kg. Indicates extensive tissue distribution, including renal and hepatic tissues.
1.2-1.8 L/kg, indicating extensive extravascular distribution.
Oral allopurinol: ~80% (mean); conversion to oxypurinol reduces systemic availability of parent drug. Food delays absorption but does not affect extent.
Oral: 60-70% (first-pass effect reduces from near-complete absorption); IM: 85-95%.
For GFR 10-20 m L/min: 200 mg/day; GFR <10 m L/min: 100 mg/day or avoid use; consider alternative in severe impairment.
GFR ≥60 m L/min: no adjustment. GFR 30-59: 200 mg twice daily. GFR <30 or hemodialysis: 200 mg once daily, after dialysis
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%.
Child-Pugh A: no adjustment. Child-Pugh B: 200 mg twice daily. Child-Pugh C: not recommended
Children 6-10 years: 100 mg orally once daily; 11-16 years: 200-300 mg orally once daily; adjust based on serum urate.
Not established for ages <12 years. For ≥12 years: weight ≥40 kg 400 mg twice daily; <40 kg 6 mg/kg twice daily, max 400 mg per dose
Start at lower end of dosing range (100-200 mg/day) due to age-related renal decline; monitor renal function and urate levels.
Start at lower end of dosing range (200 mg twice daily) due to age-related renal decline; monitor renal function
No FDA black box warning.
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.
Hypersensitivity syndrome (DRESS) may occur; discontinue at first sign of rash,Acute gout flares may occur upon initiation; prophylactic colchicine or NSAIDs recommended,Renal impairment requires dose adjustment; increase doses cautiously,Monitor liver function; hepatotoxicity reported,Bone marrow suppression (leukopenia, thrombocytopenia) may occur,Anticoagulant effect of warfarin may be enhanced
Risk of respiratory depression,Sedation in elderly,Dependence and withdrawal,Paradoxical reactions (hyperactivity, aggression),Avoid abrupt discontinuation
Hypersensitivity to allopurinol or any component,Concurrent use with azathioprine or mercaptopurine unless dose reduction is implemented
Hypersensitivity to benzodiazepines,Narrow-angle glaucoma (untreated),Severe hepatic impairment,Myasthenia gravis,Pregnancy (especially first trimester)
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat). Limit alcohol intake, particularly beer and spirits. Maintain adequate hydration. No significant food-drug interactions reported.
No specific food interactions. However, taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice as it may increase drug levels.
FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimesters: risk of fetal renal dysfunction, oligohydramnios, and neonatal renal impairment due to fetal renin-angiotensin system suppression.
First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios with prolonged use.
Small amounts of LOPURIN are excreted in breast milk. M/P ratio is approximately 0.2. The American Academy of Pediatrics considers the drug compatible with breastfeeding, but caution is advised due to potential for infant renal effects. Monitor infant for hypotension and renal function.
Excreted in breast milk; M/P ratio 0.8. Limited data suggests low infant exposure, but avoid due to potential adverse effects.
Increased plasma volume during pregnancy may reduce concentrations; dose adjustments are not routinely recommended due to variable pharmacokinetics. However, if blood pressure control is inadequate, consider increasing the dose under close monitoring. Postpartum, reduce dose to prepregnancy level to avoid hypotension.
Increased clearance during pregnancy may require 25-50% dose increase in second and third trimesters; monitor therapeutic drug levels.
Allopurinol is a xanthine oxidase inhibitor. Initiate at low dose (100 mg/day) and titrate to reduce risk of gout flares. Monitor for hypersensitivity reactions, especially in renal impairment. Doses must be adjusted for renal function (Cr Cl <60 m L/min). Do not use with azathioprine or 6-mercaptopurine without dose reduction of cytotoxic agents. Avoid restarting after severe hypersensitivity.
AMOSENE (amodiaquine) is an antimalarial used for acute uncomplicated malaria. Due to risk of hepatotoxicity and agranulocytosis, avoid repeat treatment within 8 weeks. Contraindicated in patients with liver disease or blood dyscrasias. Administer with food to reduce GI upset. Monitor LFTs and CBC if prolonged use.
Take after meals to reduce GI upset.,Drink plenty of fluids (2-3 liters/day) to prevent kidney stones.,Report any rash, itching, or swelling immediately as these may signal a serious allergic reaction.,Do not stop medication abruptly; gout flares may occur during early treatment.,Avoid alcohol, especially beer, as it can increase uric acid levels.,Keep regular appointments for blood tests to monitor uric acid and kidney function.
Take with food to minimize stomach upset.,Complete full course even if symptoms improve.,Report vomiting within 30 minutes of dose; may need repeat dose.,Avoid alcohol during therapy due to increased hepatotoxicity risk.,Notify doctor if you experience jaundice, easy bruising, or persistent sore throat.
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"The combination of allopurinol and captopril increases the risk of hypersensitivity reactions, including Stevens-Johnson syndrome and angioedema, due to a pharmacodynamic interaction that potentiates immune-mediated adverse effects. This is particularly concerning in patients with renal impairment, where both drugs may accumulate, and can lead to severe cutaneous adverse reactions or hematologic toxicities."
"Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purine analogs. Tegafur is a prodrug of 5-fluorouracil and is metabolized via the same pathway. Coadministration of allopurinol may reduce the conversion of tegafur to its active metabolite, thereby decreasing the therapeutic efficacy of tegafur. This can lead to suboptimal antineoplastic effect and potential treatment failure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOPURIN vs AMOSENE, answered by our medical review team.
LOPURIN is a Xanthine oxidase inhibitor that works by LOPURIN is a brand name for allopurinol, a xanthine oxidase inhibitor. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. AMOSENE is a Estrogen that works by Amosene is a benzodiazepine that enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, increasing chloride ion conductance and neuronal hyperpolarization, leading to anxiolytic, sedative, and muscle relaxant effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOPURIN and AMOSENE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOPURIN is: 200-600 mg orally once daily, typically starting at 300 mg/day and adjusting based on serum urate levels.. The standard adult dose of AMOSENE is: 400 mg orally twice daily for 14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOPURIN and AMOSENE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOPURIN is classified as Category C. FDA Pregnancy Category D. First trimester: risk of congenital heart defects, cleft palate, and hypospadias based on animal studies and limited human data. Second and third trimeste. AMOSENE is classified as Category C. First trimester: Human data limited, but animal studies show increased risk of cardiovascular defects. Second and third trimesters: Risk of fetal growth restriction and oligohydram. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.